These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 18279575

  • 21. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F, Lee HY.
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [Abstract] [Full Text] [Related]

  • 22. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
    Hammond-Thelin LA.
    Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
    [Abstract] [Full Text] [Related]

  • 23. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer.
    Yarom N, Jonker DJ.
    Discov Med; 2011 Feb; 11(57):95-105. PubMed ID: 21356164
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Prevention and treatment of mucocutaneous adverse reactions associated with epidermal growth factor receptor inhibitors].
    Jiang L, Xiao K, Long H.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jan 06; 56(1):87-94. PubMed ID: 35092997
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors.
    Pastore S, Lulli D, Girolomoni G.
    Arch Toxicol; 2014 Jun 06; 88(6):1189-203. PubMed ID: 24770552
    [Abstract] [Full Text] [Related]

  • 32. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash.
    Vaubel J, Livingstone E, Schadendorf D, Zimmer L.
    J Eur Acad Dermatol Venereol; 2014 Dec 06; 28(12):1685-9. PubMed ID: 24422792
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Clinical management of EGFRI dermatologic toxicities: the European perspective.
    Segaert S, Van Cutsem E.
    Oncology (Williston Park); 2007 Oct 06; 21(11 Suppl 5):22-6. PubMed ID: 18159647
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Clinical management of cutaneous toxicity of anti-EGFR agents.
    Monti M, Motta S.
    Int J Biol Markers; 2007 Oct 06; 22(1 Suppl 4):S53-61. PubMed ID: 17520582
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.